恒瑞医药(600276) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was CNY 5,845,253,168.48, representing a year-on-year increase of 2.24%[3] - The net profit attributable to shareholders for Q3 2023 was CNY 1,165,514,103.01, reflecting a year-on-year growth of 10.57%[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 1,116,896,317.22, with a year-on-year increase of 7.14%[3] - The basic earnings per share for Q3 2023 was CNY 0.18, up by 5.88% compared to the same period last year[5] - Total revenue for the first three quarters of 2023 reached CNY 17,013,632,174.61, an increase of 6.7% compared to CNY 15,945,305,398.30 in the same period of 2022[14] - Net profit for Q3 2023 reached ¥3,451,029,827.76, an increase of 11.4% compared to ¥3,096,046,599.46 in Q3 2022[16] - Operating profit for Q3 2023 was ¥3,941,329,512.97, up from ¥3,651,832,331.55 in the same period last year, reflecting a growth of 7.9%[16] - The company reported a total profit of ¥3,812,376,918.61 for Q3 2023, an increase from ¥3,533,992,695.66 in Q3 2022, reflecting a growth of 7.9%[16] Assets and Liabilities - The total assets as of September 30, 2023, amounted to CNY 42,871,390,741.49, showing a 1.22% increase from the end of the previous year[5] - The total assets as of September 30, 2023, were CNY 42,871,390,741.49, compared to CNY 42,355,009,127.70 at the end of 2022, showing an increase of 1.2%[13] - The total liabilities decreased to CNY 2,664,804,605.21 in Q3 2023 from CNY 3,941,852,984.53 in Q3 2022, a reduction of 32.4%[13] - The company reported a decrease in short-term borrowings to CNY 16,100,000.00 in Q3 2023 from CNY 1,260,943,473.97 in Q3 2022, a significant reduction of 98.7%[13] - The total equity attributable to shareholders increased to CNY 39,636,900,593.94 as of September 30, 2023, from CNY 37,823,808,247.49 at the end of 2022, reflecting a growth of 4.8%[13] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date period increased by 96.97% compared to the same period last year[7] - Cash flow from operating activities for the first nine months of 2023 was ¥4,308,871,180.92, significantly higher than ¥2,187,574,452.30 in the same period of 2022, marking a growth of 96.9%[17] - The net increase in cash and cash equivalents for Q3 2023 was ¥2,476,210,475.81, compared to ¥2,268,048,536.22 in Q3 2022, showing an increase of 9.2%[18] - The cash and cash equivalents balance at the end of Q3 2023 was ¥17,013,647,723.89, up from ¥15,388,204,624.70 at the end of Q3 2022, representing a growth of 10.6%[18] - The company's cash and cash equivalents increased to CNY 17,405,890,660.85 as of September 30, 2023, from CNY 15,110,680,633.68 at the end of 2022, representing a growth of 15.2%[12] Shareholder Information - The top shareholder, Jiangsu Hengrui Medicine Group Co., Ltd., held 1,538,184,187 shares, accounting for 24.11% of the total shares[8] - The company reported a total of 501,188 common shareholders at the end of the reporting period[8] Research and Development - Research and development expenses amounted to CNY 3,725,494,952.85 in the first three quarters of 2023, compared to CNY 3,497,538,601.73 in 2022, indicating a growth of 6.5%[14] Inventory and Costs - Operating costs for the first three quarters of 2023 were CNY 13,258,786,705.29, up from CNY 12,569,177,434.22 in 2022, reflecting a year-on-year increase of 5.5%[14] - The company’s inventory as of September 30, 2023, was CNY 2,478,935,887.62, slightly up from CNY 2,450,574,758.45 at the end of 2022, indicating a growth of 1.2%[12] Other Financial Metrics - The weighted average return on equity for Q3 2023 was 2.97%, a decrease of 0.03 percentage points year-on-year[5] - Investment income from joint ventures and associates for Q3 2023 was a loss of ¥47,114,652.44, compared to no income reported in Q3 2022[16] - The company experienced a decrease in credit impairment losses, reporting ¥3,072,103.28 in Q3 2023 compared to ¥18,036,380.59 in Q3 2022, a reduction of 83.0%[16]